{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:51:01Z","timestamp":1782208261841,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"TRON \u2013 Translationale Onkologie an der Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz gemeinn\u00fctzige GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) detection offers minimally invasive monitoring of cancer from blood samples. While tumor-informed approaches are sensitive, their clinical application is limited by cost, tissue availability, and turnaround time. In contrast, tumor-na\u00efve assays offer faster turnaround times and broader applicability, but often sacrifice sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we developed DEEPctMUT, a computational pipeline for tumor-na\u00efve ctDNA detection that integrates unique molecular identifiers (UMIs) with three complementary error-polishing strategies: (1) machine learning-based sequencing error suppression, (2) deep learning-based background noise filtering (DeepES), and (3) removal of clonal hematopoietic and germline variants using patient matched PBMC. We designed an efficient sequencing panel and developed and validated DEEPctMUT using cell lines, spike-in samples, healthy, and CRC plasma samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DEEPctMUT accurately detected mutations down to 0.03% variant allele frequency (VAF), outperforming other tumor-na\u00efve methods. In a head-to-head comparison, our pipeline identified pre-surgical CRC cases with 100% sensitivity, whereas the Roche Avenio Surveillance Kit achieved only 50% sensitivity. Furthermore, a panel-independent version of DEEPctMUT could improve the performance of Roche Avenio data without additional assay-specific training. We provide an extensive ground-truth dataset and make DEEPctMUT, including all trained models, available as an easy-to-use Nextflow pipeline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By using advanced computational error-polishing techniques, DEEPctMUT can substantially reduce technical artifacts, allowing our tumor-na\u00efve method to achieve a sensitivity comparable to tumor-informed approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-026-01694-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:34:58Z","timestamp":1782174898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-na\u00efve ctDNA detection with deep learning-enhanced error suppression for sensitive mutation calling"],"prefix":"10.1186","volume":"18","author":[{"given":"Shaya","family":"Akbarinejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Doppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos de","family":"Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Pistolic-Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca","family":"Bukur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simge","family":"\u00d6zenoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Ibn-Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1694_CR1","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.3390\/ijms25084252","volume":"25","author":"A Frydendahl","year":"2024","unstructured":"Frydendahl A, et al. Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA. Int J Mol Sci. 2024;25:4252.","journal-title":"Int J Mol Sci"},{"key":"1694_CR2","doi-asserted-by":"publisher","first-page":"e006284","DOI":"10.1136\/jitc-2022-006284","volume":"11","author":"NP Semenkovich","year":"2023","unstructured":"Semenkovich NP, et al. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. J Immunother Cancer. 2023;11:e006284.","journal-title":"J Immunother Cancer"},{"key":"1694_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","volume":"31","author":"JRM Black","year":"2025","unstructured":"Black JRM, et al. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nat Med. 2025;31:70\u20136.","journal-title":"Nat Med"},{"key":"1694_CR4","doi-asserted-by":"publisher","unstructured":"Northcott J et al Analytical Validation of NeXT Personal\u00ae, an Ultra-sensitive Personalized Circulating Tumor DNA Assay. 2024;01(17):23299863. Preprint at https:\/\/doi.org\/10.1101\/2024.01.17.23299863.","DOI":"10.1101\/2024.01.17.23299863"},{"key":"1694_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh C, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616:553\u201362.","journal-title":"Nature"},{"key":"1694_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41416-022-01716-7","volume":"126","author":"S Flach","year":"2022","unstructured":"Flach S, et al. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)\u2014a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br J Cancer. 2022;126:1186\u201395.","journal-title":"Br J Cancer"},{"key":"1694_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41416-023-02300-3","volume":"129","author":"S-B Ryoo","year":"2023","unstructured":"Ryoo S-B, et al. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer. Br J Cancer. 2023;129:374\u201381.","journal-title":"Br J Cancer"},{"key":"1694_CR8","doi-asserted-by":"publisher","unstructured":"Widman AJ, et al Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat Med. 2024;1\u201312. https:\/\/doi.org\/10.1038\/s41591-024-03040-4.","DOI":"10.1038\/s41591-024-03040-4"},{"key":"1694_CR9","doi-asserted-by":"publisher","unstructured":"Zviran A, et al Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;1\u201311. https:\/\/doi.org\/10.1038\/s41591-020-0915-3.","DOI":"10.1038\/s41591-020-0915-3"},{"key":"1694_CR10","doi-asserted-by":"crossref","unstructured":"Kurtz DM, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39:1537\u201347.","DOI":"10.1038\/s41587-021-00981-w"},{"key":"1694_CR11","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","volume":"27","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, et al. Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27:5586\u201394.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1694_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0237802","volume":"15","author":"R Woodhouse","year":"2020","unstructured":"Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One. 2020;15:e0237802.","journal-title":"PLoS ONE"},{"key":"1694_CR13","doi-asserted-by":"publisher","first-page":"e1971","DOI":"10.1002\/onco.13905","volume":"26","author":"W Al Zoughbi","year":"2021","unstructured":"Al Zoughbi W, et al. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Oncologist. 2021;26:e1971\u201381.","journal-title":"Oncologist"},{"key":"1694_CR14","doi-asserted-by":"publisher","first-page":"1153685","DOI":"10.3389\/fonc.2023.1153685","volume":"13","author":"H Jiang","year":"2023","unstructured":"Jiang H, et al. Postoperative circulating tumor DNA testing based on tumor na\u00efve strategy after liver metastasis surgery in colorectal cancer patients. Front Oncol. 2023;13:1153685.","journal-title":"Front Oncol"},{"key":"1694_CR15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41596-023-00807-w","volume":"18","author":"S Li","year":"2023","unstructured":"Li S, et al. cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA. Nat Protoc. 2023;18:1563\u201383.","journal-title":"Nat Protoc"},{"key":"1694_CR16","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1038\/s41467-021-24457-2","volume":"12","author":"S Li","year":"2021","unstructured":"Li S, et al. Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. Nat Commun. 2021;12:4172.","journal-title":"Nat Commun"},{"key":"1694_CR17","doi-asserted-by":"crossref","unstructured":"Wan JCM, Heider K, Gale D, Murphy S, Fisher E, Mouliere F, et al. ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci Transl Med. 2020;12:eaaz8084.","DOI":"10.1126\/scitranslmed.aaz8084"},{"key":"1694_CR18","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1093\/bioinformatics\/btaa053","volume":"36","author":"V Sater","year":"2020","unstructured":"Sater V, et al. UMI-VarCal: a new UMI-based variant caller that efficiently improves low-frequency variant detection in paired-end sequencing NGS libraries. Bioinformatics. 2020;36:2718\u201324.","journal-title":"Bioinformatics"},{"key":"1694_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/gr.209601.116","volume":"27","author":"T Smith","year":"2017","unstructured":"Smith T, Heger A, Sudbery I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res. 2017;27:491\u20139.","journal-title":"Genome Res"},{"key":"1694_CR20","doi-asserted-by":"crossref","unstructured":"Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022;132:e154941.","DOI":"10.1172\/JCI154941"},{"key":"1694_CR21","doi-asserted-by":"publisher","first-page":"9530","DOI":"10.1073\/pnas.1105422108","volume":"108","author":"I Kinde","year":"2011","unstructured":"Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci. 2011;108:9530\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"1694_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548\u201354.","journal-title":"Nat Med"},{"key":"1694_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman AM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:14.","journal-title":"Nat Biotechnol"},{"key":"1694_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s12859-018-2428-3","volume":"19","author":"S Deng","year":"2018","unstructured":"Deng S, et al. TNER: a novel background error suppression method for mutation detection in circulating tumor DNA. BMC Bioinformatics. 2018;19:387.","journal-title":"BMC Bioinformatics"},{"key":"1694_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41698-025-00921-w","volume":"9","author":"G Arango-Argoty","year":"2025","unstructured":"Arango-Argoty G, et al. An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples. Npj Precis Oncol. 2025;9:147.","journal-title":"Npj Precis Oncol"},{"key":"1694_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41588-024-01755-1","volume":"56","author":"N Bernstein","year":"2024","unstructured":"Bernstein N, et al. Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis. Nat Genet. 2024;56:1147\u201355.","journal-title":"Nat Genet"},{"key":"1694_CR27","unstructured":"Razavi P et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;1\u201310."},{"key":"1694_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330\u20137.","journal-title":"Nature"},{"key":"1694_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1073\/pnas.1417064112","volume":"112","author":"K Guda","year":"2015","unstructured":"Guda K, et al. Novel recurrently mutated genes in African American colon cancers. Proc Natl Acad Sci U S A. 2015;112:1149\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1694_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s13059-014-0454-7","volume":"15","author":"AR Brannon","year":"2014","unstructured":"Brannon AR, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 2014;15:454.","journal-title":"Genome Biol"},{"key":"1694_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature11282","volume":"488","author":"S Seshagiri","year":"2012","unstructured":"Seshagiri S, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012;488:660\u20134.","journal-title":"Nature"},{"key":"1694_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2019.03.030","volume":"177","author":"S Vasaikar","year":"2019","unstructured":"Vasaikar S, et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177:1035\u2013e104919.","journal-title":"Cell"},{"key":"1694_CR33","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","volume":"15","author":"M Giannakis","year":"2016","unstructured":"Giannakis M, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016;15:857\u201365.","journal-title":"Cell Rep"},{"key":"1694_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"Pan-cancer","year":"2020","unstructured":"Pan-cancer. analysis of whole genomes. Nature. 2020;578:82\u201393.","journal-title":"Nature"},{"key":"1694_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41597-022-01276-8","volume":"9","author":"B Gong","year":"2022","unstructured":"Gong B, et al. Ultra-deep sequencing data from a liquid biopsy proficiency study demonstrating analytic validity. Sci Data. 2022;9:170.","journal-title":"Sci Data"},{"key":"1694_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso P, et al. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017;35:316\u20139.","journal-title":"Nat Biotechnol"},{"key":"1694_CR37","doi-asserted-by":"publisher","first-page":"64606","DOI":"10.1109\/ACCESS.2021.3074243","volume":"9","author":"L Wang","year":"2021","unstructured":"Wang L, Han M, Li X, Zhang N, Cheng H. Review of Classification Methods on Unbalanced Data Sets. IEEE Access. 2021;9:64606\u201328.","journal-title":"IEEE Access"},{"key":"1694_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10044-003-0192-z","volume":"6","author":"R Barandela","year":"2003","unstructured":"Barandela R, Valdovinos RM, S\u00e1nchez JS. New Applications of Ensembles of Classifiers. Pattern Anal Appl. 2003;6:245\u201356.","journal-title":"Pattern Anal Appl"},{"key":"1694_CR39","doi-asserted-by":"crossref","unstructured":"Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling Somatic SNVs and Indels with Mutect2. bioRxiv. 2019;861054.","DOI":"10.1101\/861054"},{"key":"1694_CR40","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.","journal-title":"Sci Transl Med"},{"key":"1694_CR41","first-page":"3528","volume":"24","author":"OA Zill","year":"2018","unstructured":"Zill OA, et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin. Cancer Res. 2018;24:3528\u201338.","journal-title":"Cancer Res"},{"key":"1694_CR42","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","volume":"39","author":"IW Deveson","year":"2021","unstructured":"Deveson IW, et al. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 2021;39:1115\u201328.","journal-title":"Nat Biotechnol"},{"key":"1694_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","volume":"561","author":"H Lee-Six","year":"2018","unstructured":"Lee-Six H, et al. Population dynamics of normal human blood inferred from somatic mutations. Nature. 2018;561:473\u20138.","journal-title":"Nature"},{"key":"1694_CR44","doi-asserted-by":"publisher","first-page":"eabe3722","DOI":"10.1126\/sciadv.abe3722","volume":"6","author":"S Abelson","year":"2020","unstructured":"Abelson S, et al. Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing. Sci Adv. 2020;6:eabe3722.","journal-title":"Sci Adv"},{"key":"1694_CR45","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1038\/s41467-021-24109-5","volume":"12","author":"A Rose Brannon","year":"2021","unstructured":"Rose Brannon A, et al. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat Commun. 2021;12:3770.","journal-title":"Nat Commun"},{"key":"1694_CR46","doi-asserted-by":"publisher","first-page":"e1006162","DOI":"10.1371\/journal.pgen.1006162","volume":"12","author":"HR Underhill","year":"2016","unstructured":"Underhill HR, et al. Fragment Length of Circulating Tumor DNA. PLOS Genet. 2016;12:e1006162.","journal-title":"PLOS Genet"},{"key":"1694_CR47","doi-asserted-by":"publisher","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","volume":"10","author":"F Mouliere","year":"2018","unstructured":"Mouliere F, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10:eaat4921.","journal-title":"Sci Transl Med"},{"key":"1694_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1073\/pnas.1421839112","volume":"112","author":"C Tomasetti","year":"2015","unstructured":"Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci. 2015;112:118\u201323.","journal-title":"Proc Natl Acad Sci"},{"key":"1694_CR49","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.cell.2020.01.032","volume":"180","author":"S Kumar","year":"2020","unstructured":"Kumar S, et al. Passenger mutations in 2500 cancer genomes: Overall molecular functional impact and consequences. Cell. 2020;180:915\u2013e92716.","journal-title":"Cell"},{"key":"1694_CR50","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/nar\/gkz474","volume":"47","author":"TT Wang","year":"2019","unstructured":"Wang TT, et al. High efficiency error suppression for accurate detection of low-frequency variants. Nucleic Acids Res. 2019;47:e87.","journal-title":"Nucleic Acids Res"},{"key":"1694_CR51","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/nprot.2014.170","volume":"9","author":"SR Kennedy","year":"2014","unstructured":"Kennedy SR, et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc. 2014;9:2586\u2013606.","journal-title":"Nat Protoc"},{"key":"1694_CR52","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13059-021-02528-3","volume":"22","author":"TR Mercer","year":"2021","unstructured":"Mercer TR, Xu J, Mason CE, Tong W, on behalf of the MAQC\/SEQC2 Consortium. The Sequencing Quality Control 2 study: establishing community standards for sequencing in precision medicine. Genome Biol. 2021;22:306.","journal-title":"Genome Biol"},{"key":"1694_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13059-021-02316-z","volume":"22","author":"W Jones","year":"2021","unstructured":"Jones W, et al. A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency. Genome Biol. 2021;22:111.","journal-title":"Genome Biol"},{"key":"1694_CR54","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature. 2017;545:446\u201351.","journal-title":"Nature"},{"key":"1694_CR55","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41431-022-01134-6","volume":"30","author":"G Corso","year":"2022","unstructured":"Corso G. Microsatellite instability in gastrointestinal cancers. Eur J Hum Genet. 2022;30:996\u20137.","journal-title":"Eur J Hum Genet"},{"key":"1694_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13073-023-01204-4","volume":"15","author":"P Sanjaya","year":"2023","unstructured":"Sanjaya P, et al. Mutation-Attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping. Genome Med. 2023;15:47.","journal-title":"Genome Med"},{"key":"1694_CR57","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1186\/s12885-020-07445-5","volume":"20","author":"S Verma","year":"2020","unstructured":"Verma S, et al. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma. BMC Cancer. 2020;20:945.","journal-title":"BMC Cancer"},{"key":"1694_CR58","doi-asserted-by":"publisher","first-page":"e0266889","DOI":"10.1371\/journal.pone.0266889","volume":"17","author":"L Yu","year":"2022","unstructured":"Yu L, et al. Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels. PLoS ONE. 2022;17:e0266889.","journal-title":"PLoS ONE"},{"key":"1694_CR59","doi-asserted-by":"publisher","first-page":"e2300127","DOI":"10.1200\/PO.23.00127","volume":"8","author":"OE Emiloju","year":"2024","unstructured":"Emiloju OE, et al. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. JCO Precis Oncol. 2024;8:e2300127.","journal-title":"JCO Precis Oncol"},{"key":"1694_CR60","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert T, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019;5:1124\u201331.","journal-title":"JAMA Oncol"},{"key":"1694_CR61","doi-asserted-by":"crossref","unstructured":"Nakamura Y et al. Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay. Clin Cancer Res OF. 2024;1\u2013OF11.","DOI":"10.1158\/1078-0432.27142362"},{"key":"1694_CR62","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2021.39.3_suppl.102","volume":"39","author":"G Anandappa","year":"2021","unstructured":"Anandappa G, et al. Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC). J Clin Oncol. 2021;39:102\u2013102.","journal-title":"J Clin Oncol"},{"key":"1694_CR63","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","volume":"30","author":"N Tarazona","year":"2019","unstructured":"Tarazona N, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:1804\u201312.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1694_CR64","doi-asserted-by":"publisher","first-page":"1055968","DOI":"10.3389\/fonc.2022.1055968","volume":"12","author":"HT Chan","year":"2023","unstructured":"Chan HT, et al. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Front Oncol. 2023;12:1055968.","journal-title":"Front Oncol"},{"key":"1694_CR65","first-page":"4365","volume":"15","author":"X Sun","year":"2018","unstructured":"Sun X, et al. Monitoring colorectal cancer following surgery using plasma circulating tumor DNA. Oncol Lett. 2018;15:4365\u201375.","journal-title":"Oncol Lett"},{"key":"1694_CR66","unstructured":"Akbarinejad S, et al. TRON tumor-na\u00efve ctDNA detection. 2026. https:\/\/www.ebi.ac.uk\/ena\/browser\/view\/PRJEB113702."},{"key":"1694_CR67","unstructured":"Akbarinejad S, et al. DEEPctMUT. 2026. https:\/\/github.com\/TRON-Bioinformatics\/DEEPctMUT."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01694-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:23:27Z","timestamp":1782206607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01694-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1694"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01694-y","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research project was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All human samples were commercially purchased and collected under informed written consent with explicit permission for DNA testing and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ugur Sahin is a co-founder, Chief Executive Officer, and shareholder of BioNTech SE. Christian Albrecht und Sarah Doppler are employees of BioNTech SE.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}